CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN

被引：0
|
作者：
Moreno Guillen, S. [1 ]
Rivero, A. [2 ]
Ventayol, P. [3 ]
Falco, V. [4 ]
Torralba, M. [5 ]
Schroeder, M. [6 ]
Neches, V. [7 ]
Vallejo-Aparicio, L. A. [7 ]
Mackenzie, I. [8 ]
Turner, M. [9 ]
Harrison, C. [9 ]
机构：
[1] Hosp Ramon & Cajal, Madrid, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Univ Son Espases, Palma De Mallorca, Spain
[4] Hosp Valle De Hebron, Barcelona, Spain
[5] Hosp Univ Guadalajara, Guadalajara, Spain
[6] ViiV Healthcare, Brentford, England
[7] GSK, Tres Cantos, Spain
[8] Hlth Econ & Outcomes Res Ltd, Stratford Upon Avon, War, England
[9] Hlth Econ & Outcomes Res Ltd, Cardiff, Crf, Wales
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE345
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [41] Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
    Fernandez, Cristina
    van Halsema, Clare L.
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2019, 11 : 179 - 192
  • [42] Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk
    Masia, Mar
    Fernandez-Gonzalez, Marta
    Ledesma, Christian
    Losada-Echeberria, Maria
    Gonzalo-Jimenez, Nieves
    Mascarell, Paula
    Garcia-Abellan, Javier
    Lopez, Leandro
    Bello-Perez, Melissa
    Padilla, Sergio
    Gutierrez, Felix
    JOURNAL OF INFECTIOUS DISEASES, 2025,
  • [43] Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection
    Zeuli, John D.
    Rivera, Christina G.
    Smith, Bradley L.
    Otto, Ashley
    Temesgen, Zelalem
    DRUGS OF TODAY, 2022, 58 (12) : 555 - 576
  • [44] Long-acting injectable antiretroviral for HIV-1 infection in adults
    Halani, Sheliza
    Tan, Darrell
    Andany, Nisha
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (25) : E888 - E889
  • [45] Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
    Michael G. Sension
    Laurence Brunet
    Ricky K. Hsu
    Jennifer S. Fusco
    Quateka Cochran
    Christine Uranaka
    Gayathri Sridhar
    Vani Vannappagari
    Jean Van Wyk
    Lewis McCurdy
    Michael B. Wohlfeiler
    Gregory P. Fusco
    Infectious Diseases and Therapy, 2023, 12 : 2807 - 2817
  • [46] Learning From Full Characterization of HIV Proviruses in People Receiving Long-Acting Cabotegravir/Rilpivirine With a History of Replication on the Antiretroviral Classes
    Mchantaf, Gilbert
    Chaillon, Antoine
    Charre, Caroline
    Melard, Adeline
    Gardiennet, Elise
    Guinard, Jerome
    Prazuck, Thierry
    Guillaume, Clemence
    Mariaggi, Alice-Andree
    Bois, Julie
    Hocqueloux, Laurent
    Avettand-Fenoel, Veronique
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (01):
  • [47] Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results
    Margolis, D.
    Podzamczer, D.
    Stellbrink, H-J
    Lutz, T.
    Angel, J.
    Richmond, G.
    Clotet, B.
    Gutierrez, F.
    Sloan, L.
    Griffith, S.
    St Clair, M.
    Dorey, D.
    Ford, S.
    Mrus, J.
    Crauwels, H.
    Smith, K.
    Williams, P.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [48] Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol
    Wu, Yuan-ni
    Yu, Hai
    Lu, Lianfeng
    Li, Xiaodi
    Liu, Xiaosheng
    Cao, Wei
    Li, Taisheng
    BMJ OPEN, 2022, 12 (12):
  • [49] Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis
    Manalu, Samuel Bungaran Partahi Saud
    Navarro, Andrea Perez
    Fairhead, Cassandra
    Hill, Andrew
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025, 80 (03) : 624 - 632
  • [50] Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort
    Borch, J.
    Scherzer, J.
    Jonsson-Oldenbuettel, C.
    Weinberg, G.
    Wyen, C.
    Rodriguez, E.
    Scholten, S.
    Dakhia, S.
    Dymek, K.
    Westermayer, B.
    Bernhardt, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 20 - 21
12345